MIA Calculator for Predicting Recurrence-Free and Overall Survival in Stage II Melanoma
Source: The Asco Post, February 2024
In a study reported in the Journal of Clinical Oncology, Varey et al developed the Melanoma Institute Australia (MIA) calculator for predicting recurrence-free and overall survival in stage II melanoma and found that it outperformed modeling based on American Joint Committee on Cancer (AJCC)-8th edition melanoma staging.
Study Details
The study involved data on 3,220 patients from the MIA database diagnosed with clinical or pathologic stage II melanoma. Prediction models were developed using multivariate Cox regression analyses (MIA models) and externally validated using data sets from the United States and the Netherlands. Model performance was assessed using C-statistics and calibration plots and compared with Cox models based on AJCC-8th edition staging (stage models). The final MIA calculator for recurrence-free survival included: age, Breslow thickness, sex, ulceration, satellites, lymphovascular invasion, tumor-infiltrating lymphocytes, regression, sentinel node biopsy status, melanoma subtype, primary lesion site, and mitosis. The calculator for overall survival included: age, Breslow thickness, sex ulceration, tumor-infiltrating lymphocytes, sentinel node biopsy status, melanoma subtype, and mitosis.
Key Findings
For the MIA model vs the stage model, 5-year recurrence-free survival C-statistics were 0.70 vs 0.61 and 10-year recurrence-free survival C-statistics were 0.73 vs 0.60.